CD8A and neoplasm: In the study of Kano Y et al., the soluble recombinant protein LAG-3-Ig, which inhibits the LAG-3 signal, was combined with a tumor vaccine, and it was found that they could down-regulate the expression of LAG-3 and other co-inhibitory receptors on CD8+ T cells, prevent Tex, and boost the tumor vaccine’s therapeutic impact in concert (179).